Hongtao Duan
Papers
1
Total Citations
53
H-Index
1
About
Dr. Hongtao Duan is a leading oncologist and clinical researcher whose work focuses on neoadjuvant immunotherapy for resectable non-small cell lung cancer (NSCLC). His major contributions center on integrating programmed cell death protein 1 (PD-1) inhibitors with chemotherapy prior to surgery, a strategy that has shown remarkable promise in improving outcomes for patients with early-stage disease. His landmark 2021 study, an open-label, multicenter, single-arm trial, demonstrated the safety and efficacy of this combined approach, achieving a major pathological response rate that significantly exceeded historical benchmarks. This work, which has garnered over 50 citations, builds upon seminal trials like CheckMate 159 and pushes the field toward more effective, less toxic preoperative regimens. Dr. Duan’s research is helping to reshape the standard of care for resectable NSCLC, offering patients a better chance at long-term survival. His ongoing investigations continue to refine patient selection and optimize treatment protocols, cementing his reputation as a key figure in the rapidly evolving landscape of lung cancer immunotherapy.
Research Focus
Key Achievements
Top Papers
- 1